iMCD can present as an acute life-threatening disease in some patients or a chronic disease in others. Some patients have longstanding stable disease while others suffer flares of severe disease that may improve with treatment. Successful treatment controls symptoms and organ dysfunction associated with iMCD, improves symptoms and organ dysfunction during disease flares, and prevents future disease flares. Observed survival in a recent study of iMCD patients was 92% at 2 years, 76% at 5 years, and 59% at 10 years.
Idiopathic multicentric Castleman disease
Unicentric Castleman disease
Chronic multifocal Langerhans cell histiocytosis
Follicular lymphoma
Fibrin-associated diffuse large B-cell lymphoma
HHV-8-associated MCD
AIDS-related lymphoma
Progressive nodular histiocytoma